{{Rsnum
|rsid=6782400
|Gene=ATR
|Chromosome=3
|position=142576526
|Orientation=plus
|GMAF=0.3811
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=ATR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 25.7 | 55.8 | 18.6
| HCB | 32.1 | 43.1 | 24.8
| JPT | 18.8 | 55.4 | 25.9
| YRI | 80.8 | 17.8 | 1.4
| ASW | 64.3 | 26.8 | 8.9
| CHB | 32.1 | 43.1 | 24.8
| CHD | 16.7 | 54.6 | 28.7
| GIH | 15.0 | 59.0 | 26.0
| LWK | 77.8 | 19.4 | 2.8
| MEX | 21.8 | 61.8 | 16.4
| MKK | 72.9 | 24.5 | 2.6
| TSI | 37.6 | 55.4 | 6.9
| HapMapRevision=28
}}

{{PMID|18451257}} [[rs8178085]] and [[rs12334811]] with approaching dose-dependent effect on [[lung cancer]] predisposition, subjects carrying two to four risk genotypes were associated with a 43% decreased lung cancer risk compared with subjects carrying zero to one risk genotypes (adjusted odds ratio, 0.53; 95% confidence interval, 0.35-0.80).

Moreover, the decreased risk associated with the combined genotypes of [[rs8178085]] and [[rs12334811]] was slightly more pronounced in nonsmokers and in carriers with ataxia-telangiectasia mutated [[rs228591]] variant allele or ataxia-telangiectasia and Rad3-related [[rs6782400]] wild-type homozygous genotype.

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}